Dia.Pro Diagnostic Bioprobes s.r.l products

Chemi-Luminescence ImmunoAssay (CLIA) for the quantitative determination of antibodies to COVID-19 Virus (SARS-CoV-2) Spike/RBD in human plasma and sera.

Chemi-Luminescence ImmunoAssay (CLIA) for the serological determination of the neutralization activity of antibodies to SARS-CoV-2, induced by natural infection and/or vaccination, able to block the interaction of Receptor Binding Domain (RBD) and ACE2 and thus the virus infection.

Chemi-Luminescence ImmunoAssay (CLIA) for the semi-quantitative determination of IgG antibodies to SARS-CoV-2 Nucleocapsid protein (NCP) in human plasma and sera. The kit is intended for monitoring of infected patients. In addition the kit may be used when testing the population and health-care workers looking for potentially infective “pauci” or a-symptomatic individuals in the early phase of infection, in combination with SARS-COV-2 molecular tests. The device has been adapted for the use in exclusive combination with the Dia.Pro CLIA random access instrument named SARA.